Drug profile · INN
praziquantel
DISTOCIDE (KOREA)
praziquantel (DISTOCIDE (KOREA)) is a voltage-activated calcium channel beta 1 subunit blocker. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — praziquantel
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
praziquantel (DISTOCIDE (KOREA)) is a voltage-activated calcium channel beta 1 subunit blocker. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Voltage-activated calcium channel beta 1 subunit blocker
Primary target: Voltage-activated calcium channel beta 1 subunit
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Frequently asked questions
What is praziquantel?
praziquantel (DISTOCIDE (KOREA)) is a voltage-activated calcium channel beta 1 subunit blocker. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for praziquantel?
DISTOCIDE (KOREA) is a marketed brand name for praziquantel. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of praziquantel?
praziquantel has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.